Professor John Robertson OBA In the Independent yesterday, the above, and: Enhertu is the first licensed targeted treatment for patients with HER2-low breast cancer that cannot be removed surgically or that has spread to other parts of the body. Patients are usually offered chemotherapy, but Breast Cancer Now explains the targeted drug could offer people more time to live in comparison. Enhertu was approved for use in Scotland in December 2023 but was rejected for use on NHS England in March 2024 by the National Institute of Health and Care Excellence (Nice) because it was too expensive. In September 2023, 84 patients have to … Continue reading How NHS Scotland repeatedly has and can help NHS England patients